Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

Voyageur Pharmaceuticals Ltd. (VM) has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG, triggering a USD $1,000,000 payment. The company successfully validated its proprietary Mueller iodine extraction process, achieving 99.8% purity iodine from Anadarko Basin produced water in laboratory settings.

Total funding received to date stands at USD $1,350,000, including the initial USD $350,000. The remaining USD $1,000,000 milestone is scheduled upon completion of the FEL-3 feasibility study. A transportable pilot plant is nearing completion and is scheduled for field operations in fall 2026.

Fluor Corporation is supporting the engineering and thermodynamic modeling for the feasibility study, targeting a practical demonstration-scale configuration for modular Field Unit plus Central Hub architecture. Proposed production capacity is 1,000 tonnes per year, with an initial staged production of 200 tonnes per year.

Voyageur Pharmaceuticals Ltd. (VM) received a milestone payment following its February 2026 collaboration agreement, a development the market had fully anticipated. The payment confirms technical progress and validates the Mueller process using real oilfield brine, aligning with prior updates from August 2026 that demonstrate consistent execution against the announced roadmap.

The USD $1 million injection provides critical non-dilutive liquidity to the company, which is currently facing a going concern warning. However, this funding does not alter the fundamental development timeline or long-term capital requirements. While the news de-risks the Bayer project slightly, Voyageur remains reliant on the second milestone, pilot plant field results, and future equity raises to fund the planned GMP manufacturing facility.

Voyageur Pharmaceuticals Ltd. (VM) is a pre-revenue Canadian company developing a vertically integrated supply chain for barium and iodine contrast media used in medical imaging. The company’s flagship operations include the Frances Creek barite project in British Columbia, which holds a mineral resource of 214,800 tonnes at 35.2% BaSO4 (indicated) and 134,200 tonnes at 33.9% BaSO4 (inferred). Recent testing confirms pharmaceutical-grade purity, averaging 98.8% BaSO4.

The second flagship project is the Bayer iodine extraction project in Oklahoma. This operation utilizes the acquired Mueller Process to extract high-purity iodine from oilfield produced water. Voyageur’s strategic goal is to become the only vertically integrated producer of both barium and iodine contrast agents in North America, targeting a GMP manufacturing facility by 2027.